Anke M. Hövels

2.7k total citations · 1 hit paper
56 papers, 1.9k citations indexed

About

Anke M. Hövels is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Anke M. Hövels has authored 56 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Economics and Econometrics, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Anke M. Hövels's work include Health Systems, Economic Evaluations, Quality of Life (26 papers), Pharmaceutical Economics and Policy (15 papers) and Economic and Financial Impacts of Cancer (6 papers). Anke M. Hövels is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (26 papers), Pharmaceutical Economics and Policy (15 papers) and Economic and Financial Impacts of Cancer (6 papers). Anke M. Hövels collaborates with scholars based in Netherlands, United Kingdom and United States. Anke M. Hövels's co-authors include Jelle O. Barentsz, Roel A. M. Heesakkers, Johan L. Severens, Eddy Adang, Yvonne L. Hoogeveen, G.J. Jager, Stephen B. Strum, Gerrit J. Jager, J. Alfred Witjes and Hubert G. M. Leufkens and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Radiology.

In The Last Decade

Anke M. Hövels

52 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

2008 687 citations Anke M. Hövels, Johan L. Severens et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anke M. Hövels Netherlands	18	941	498	284	284	194	56	1.9k
D.A. Loblaw Canada	29	2.5k 2.7×	487 1.0×	185 0.7×	94 0.3×	118 0.6×	88	3.4k
Alan P. Lyss United States	27	879 0.9×	262 0.5×	151 0.5×	150 0.5×	189 1.0×	66	2.7k
Hung‐Jui Tan United States	16	912 1.0×	203 0.4×	114 0.4×	155 0.5×	69 0.4×	74	2.2k
H. Ballentine Carter United States	16	2.0k 2.1×	267 0.5×	534 1.9×	86 0.3×	40 0.2×	24	2.4k
Colin O’Donnell United States	20	440 0.5×	425 0.9×	500 1.8×	49 0.2×	46 0.2×	70	1.7k
Trevor J. Royce United States	25	695 0.7×	481 1.0×	75 0.3×	274 1.0×	29 0.1×	134	2.1k
Sanoj Punnen United States	22	1.0k 1.1×	242 0.5×	223 0.8×	43 0.2×	40 0.2×	98	1.8k
Erin Kirkby United States	16	1.6k 1.7×	266 0.5×	414 1.5×	93 0.3×	31 0.2×	24	2.4k
Drew Moghanaki United States	21	1.3k 1.3×	409 0.8×	77 0.3×	52 0.2×	74 0.4×	118	2.2k
Timothy J. Daskivich United States	26	961 1.0×	149 0.3×	73 0.3×	204 0.7×	57 0.3×	97	2.0k

Countries citing papers authored by Anke M. Hövels

Since Specialization

Citations

This map shows the geographic impact of Anke M. Hövels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke M. Hövels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke M. Hövels more than expected).

Fields of papers citing papers by Anke M. Hövels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke M. Hövels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke M. Hövels. The network helps show where Anke M. Hövels may publish in the future.

Co-authorship network of co-authors of Anke M. Hövels

This figure shows the co-authorship network connecting the top 25 collaborators of Anke M. Hövels. A scholar is included among the top collaborators of Anke M. Hövels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke M. Hövels. Anke M. Hövels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vreman, Rick A., et al.. (2020). Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. Cost Effectiveness and Resource Allocation. 18(1). 54–54. 2 indexed citations

Vreman, Rick A., Svetlana V. Belitser, Anke M. Hövels, et al.. (2020). Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology. 86(7). 1306–1313. 10 indexed citations

Hövels, Anke M., et al.. (2020). Cost‐utility and cost‐effectiveness analysis of a clinical medication review focused on personal goals in older persons with polypharmacy compared to usual care: Economic evaluation of the DREAMeR study. British Journal of Clinical Pharmacology. 87(2). 588–597. 16 indexed citations

Ham, Renske M.T. ten, Merel van Nuland, Rick A. Vreman, et al.. (2020). Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health. 24(1). 121–128. 4 indexed citations

Belitser, Svetlana V., et al.. (2020). A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. The European Journal of Health Economics. 21(6). 845–853. 1 indexed citations

Vreman, Rick A., et al.. (2019). Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy. 17(6). 883–893. 14 indexed citations

Frederix, G. W. J., et al.. (2019). Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. PharmacoEconomics - Open. 4(2). 223–233. 1 indexed citations

Boersma, Cornelis, et al.. (2019). Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. The European Journal of Health Economics. 20(6). 857–867. 7 indexed citations

Bekker, Charlotte L., Helga Gardarsdóttir, Toine C. G. Egberts, et al.. (2019). What does it cost to redispense unused medications in the pharmacy? A micro-costing study. BMC Health Services Research. 19(1). 243–243. 21 indexed citations

10.

Nuland, Merel van, Rick A. Vreman, Renske M.T. ten Ham, et al.. (2018). Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. Breast Cancer Research and Treatment. 172(1). 143–150. 10 indexed citations

11.

McAuslane, Neil, et al.. (2017). Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures—Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions. Value in Health. 21(6). 707–714. 34 indexed citations

12.

Hövels, Anke M., et al.. (2017). The Introduction Of A Threshold For The Icer And The Implications For Reimbursement Of Drugs In The Dutch Healthcare System. Value in Health. 20(9). A671–A671. 6 indexed citations

13.

Weger, Vincent A. de, et al.. (2017). Changing costs of metastatic non small cell lung cancer in the Netherlands. Lung Cancer. 114. 56–61. 8 indexed citations

14.

Monroe, Glen R., G. W. J. Frederix, Sanne M. C. Savelberg, et al.. (2016). Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genetics in Medicine. 18(9). 949–956. 125 indexed citations

15.

Asselbergs, Folkert W., et al.. (2016). Early HTA in Pharmacogenomics: A Case Example in Cardiovascular Drugs. Value in Health. 19(7). A636–A636. 1 indexed citations

16.

Frederix, Geert, Anke M. Hövels, Johan L. Severens, Jan A. M. Raaijmakers, & Jan H.M. Schellens. (2015). [Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and modelling are essential links].. PubMed. 159. A7728–A7728.

17.

Frederix, G. W. J., Johan L. Severens, Anke M. Hövels, et al.. (2014). Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. European Journal of Cancer Care. 24(3). 340–354. 4 indexed citations

18.

Hövels, Anke M., et al.. (2013). The Association Between European Medicines Agency Approval and Health Technology Assessment Recommendation. Value in Health. 16(7). A455–A455. 2 indexed citations

19.

Frederix, G. W. J., Johan L. Severens, Anke M. Hövels, Jan A. M. Raaijmakers, & Jan H.M. Schellens. (2013). The Cloudy Crystal Ball of Cost-Effectiveness Studies. Value in Health. 16(6). 1100–1102. 12 indexed citations

20.

Frederix, G. W. J., Johan L. Severens, Anke M. Hövels, Jan A. M. Raaijmakers, & Jan H.M. Schellens. (2011). Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes. Value in Health. 15(1). 94–105. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact